Sun Pharmaceutical Industries Limited
Overview
Sun Pharmaceutical Industries Limited is the listed parent of a global pharmaceutical group. Its businesses include generic and branded formulations, innovative medicines, active pharmaceutical ingredients and consumer-health products. A formulation is the finished medicine supplied in a particular dosage form; an active ingredient is an input used to make it. These activities connect scientific development, regulatory approval, manufacturing and distribution, with different commercial models across markets. [1][10]
Sun’s familiar founding story begins in 1983, while its current listed legal entity was incorporated in 1993. The distinction matters when comparing a business history with a corporate registry. The group is managed from Mumbai, with its registered office in Vadodara. Its medicines and brands operate through multiple entities and country-specific approvals, so a global product list should not be read as a statement that every product is sold everywhere. [2][3][10]
Company identity & key facts
| Field | Details |
|---|---|
| Legal name | Sun Pharmaceutical Industries Limited |
| Business origins | 1983, founded by Dilip Shanghvi |
| Incorporation year | 1993, distinct from the 1983 business origins |
| CIN | L24230GJ1993PLC019050 |
| Public trading | NSE: SUNPHARMA · BSE: 524715 |
| Corporate base | Mumbai, Maharashtra, India |
| Corporate office | Sun House, CTS No. 201 B/1, Western Express Highway, Goregaon East, Mumbai 400063 |
| Registered office | SPARC, Tandalja, Vadodara 390012, Gujarat |
| Executive Chairman | Dilip Shanghvi |
| Managing Director | Kirti Ganorkar |
| Financial year | 1 April–31 March |
| Website | sunpharma.com |
The word SPARC in the registered-office address should not be used to merge the listed manufacturer with Sun Pharma Advanced Research Company. The leadership page identifies Dilip Shanghvi’s role at that research company separately. An address, shared founder or common brand element is not sufficient to establish that two companies have the same accounts or shareholders. [3][4]
History & selected milestones
- 1983The business starts with five psychiatry products and a manufacturing facility at Vapi, Gujarat.
- 1991The company’s history records its first research centre.
- 1993The present listed legal entity is incorporated.
- 1994The company records its initial public offering.
- 1995API production begins at Panoli, Gujarat.
- 1997An initial investment in Caraco marks an international acquisition step.
- 2023Concert Pharmaceuticals is acquired in the United States.
- 2025Checkpoint Therapeutics is acquired; Kirti Ganorkar becomes Managing Director from 1 September.
- 2026A definitive agreement to acquire Organon is announced; the October results still describe remaining regulatory approvals and integration planning.
These milestones describe selected changes in the business. The original records provide the fuller chronology. [2][3][5][9][7]
How the business makes money
Sun develops or obtains rights to products, secures the relevant approvals, manufactures or sources supplies and sells through healthcare distribution channels. The route differs between prescription generics, branded products, innovative medicines and consumer health. API sales also serve other pharmaceutical manufacturers. A patient may see the medicine brand while the legal supplier, distributor and manufacturing site are identified elsewhere in the product documentation. [10][11]
Analytical context: pharmaceuticals combine long development and approval cycles with recurring demand for established products. Pricing, competition, launch timing, intellectual-property rights and production reliability influence profitability. An approval is a regulatory milestone, while a commercial launch, prescription uptake and recognised sales are later events. Licensing can confer rights in selected territories rather than global ownership, making the geographical terms of a deal important. [11][6]
Major business activities
Formulations supply finished medicines across different therapeutic areas and markets. India, the United States, emerging markets and the rest-of-world businesses have different customer channels and reimbursement environments. Innovative medicines are a product category across those geographies, not a separate territory that can simply be added to all regional sales. This prevents double counting when reading a results presentation. [10][7]
The API business supports internal formulation production and external customers. The products page describes chemistry-intensive ingredients, intermediates and custom-synthesis activities. Analytical context: internal production can support supply control, but does not remove the need for quality systems, process validation and reliable raw-material sourcing. API tonnes and finished-medicine unit counts are different industrial measures. [10]
Consumer health includes familiar names such as Revital, Volini and Faringosept. Its commercial relationships can involve consumer marketing and retail distribution rather than the same channel as a specialist prescription product. This profile identifies the businesses and brands for corporate orientation; it does not recommend a medicine or make a claim about its suitability for an individual. [10]
Brands, products & entities
| Name | What it identifies |
|---|---|
| Sun Pharma | The main corporate and group identity. |
| ILUMYA, CEQUA and LEQSELVI | Examples of the innovative or specialty portfolio described in dated company milestones and releases. |
| Revital, Volini and Faringosept | Selected consumer-health brands listed on the product page. |
| Sun Pharma Laboratories Limited | A separate Indian operating subsidiary; consult its own report for entity-specific accounts. |
| Taro | A group operating-company identity, with subsidiary reports available through the parent’s directory. |
| Checkpoint Therapeutics | A US acquisition recorded in the company’s 2025 history. |
| Organon | The subject of an agreed acquisition whose remaining approvals and integration planning were still discussed on 30 October 2026. |
| Sun Pharma Advanced Research Company | A separately identified research company; common leadership does not combine its accounts with the listed manufacturer. |
Brand rights may differ by territory, formulation or agreement. Product availability also depends on the local regulator and market launch. The original product and licensing documents are necessary for a precise claim about ownership or commercialisation rights in a particular country. [10][6]
Group structure & acquisition boundaries
The consolidated accounts describe the parent and entities included under the applicable accounting standards; standalone statements describe the listed Indian company alone. Sun publishes subsidiary accounts separately, allowing a reader to trace local operating entities without treating every group name as the listed issuer. Business segments, geographic sales categories and legal companies are three different ways to describe the same group. [6][13]
Acquisitions have helped expand its geographic and product portfolio. The April 2026 Organon document is a definitive-agreement announcement, not a completion notice. The 30 October results release says integration planning was progressing and approvals had been secured in a majority of regions, with other jurisdictions still in progress. This profile therefore does not count Organon as a completed acquisition or add its historic revenue to Sun’s reported results. [9][7]
Analytical context: acquisition price, enterprise value, debt assumed and accounting revenue are distinct amounts. Consolidation starts according to the applicable control and accounting rules, not simply because a deal has attracted attention. Subsequent filings are essential when updating a group profile after an agreement. [9][6]
Leadership, shareholding & governance
Dilip Shanghvi is the founder and Executive Chairman. Kirti Ganorkar is Managing Director, following the transition effective 1 September 2025. The reviewed board page confirms the current titles, so an older description of the founder as the serving Managing Director would be misleading. Board oversight, executive management and responsibility for an individual business or country are separate roles. [4][5]
Quarterly shareholding patterns identify promoter and public holdings at specified dates. This profile avoids assigning an undated ownership percentage to an individual or family. The annual governance report covers board committees, related-party transactions and policies. Analytical context: the combination of founding-family influence, global subsidiaries and acquisition activity makes capital allocation and independent oversight relevant subjects for review, without implying a finding of misconduct. [14][6]
Corporate base, research & manufacturing
Mumbai is the corporate base, while the registered office is at Tandalja in Vadodara, Gujarat. The historic manufacturing story begins at Vapi and later includes API production at Panoli. Those origins do not constitute a complete current plant list. The current annual and subsidiary reports are more appropriate for identifying legal ownership and operations after acquisitions or disposals. [3][2][13]
The innovation page describes capabilities in formulation development, process chemistry, analytical work and drug-delivery technologies, including research activity across several countries. A research centre, commercial office, API plant and finished-dose facility have different functions. Analytical context: a manufacturing site is approved for particular activities and products; the existence of a global network does not mean every site can supply every market or dosage form. [11][12]
Use the official contact page for a country or corporate enquiry. Investor correspondence, product-quality reporting and recruitment have different channels, helping information reach the team responsible for it. [15][16]
Dated financial context
| Q2 FY2026–27 consolidated measure | INR million unless stated |
|---|---|
| Period | Quarter ended 30 September 2026; release dated 30 October 2026 |
| Sales | 161,000 |
| EBITDA | 47,439 |
| EBITDA margin, issuer-reported | 29.3% |
| Profit before exceptional items and tax | 44,282 |
| Reported net profit | 19,885 |
| Adjusted net profit, issuer-reported | 31,620 |
| R&D investment | 7,784 |
These are consolidated quarterly figures, not standalone accounts or a full-year run rate. One crore equals ten million rupees. The release distinguishes reported net profit from adjusted net profit; the adjusted measure must not be substituted for the reported result. Its innovative-medicine sales category overlaps the geographical business presentation, so adding both sets of categories would overstate group sales. [7]
The statutory notes disclose September-quarter exceptional charges of ₹3,461.6 million for Organon acquisition-related costs and ₹9,226.7 million for a settlement agreement dated 10 September 2026 with one antitrust-litigation plaintiff, with a ₹953.4 million related tax benefit. Removing those net charges reconciles reported and adjusted profit at the release’s rounded precision. The settlement agreement should not be read as resolution of every litigation matter. [8]
Research, innovation & portfolio strategy
Sun’s research approach combines generics, complex formulations, APIs and innovative products. The innovation page describes delivery technologies such as inhalation, ophthalmic, topical and injectable formulations. Developing a difficult dosage form can create a commercial capability, but it still requires successful validation, regulatory review, manufacturing and launch. A pipeline milestone is not equivalent to an approved product or established revenue stream. [11]
Its portfolio has also developed through acquisitions and licences. Analytical context: building a specialty business can involve clinical development, medical affairs, market access and a different sales organisation from a high-volume generic portfolio. Territory-specific agreements can broaden access while limiting which countries contribute to a licensee’s sales. The Organon agreement represents a further strategic proposal, whose completion status should remain distinct from management’s intended benefits. [9][11]
People, quality culture & careers
Pharmaceutical operations bring together scientists, manufacturing staff, quality professionals, regulatory teams, commercial employees and support functions. Sun’s quality page describes a global quality-management framework, documentation, training and lessons learned from identified gaps. These statements describe the company’s operating approach; they are not a regulator’s certification that every facility is free from unresolved issues. [12]
Analytical context: process discipline depends on people maintaining records, investigating deviations and escalating problems as well as on equipment. Training, retention and consistent standards become especially important when organisations grow through acquisitions. The official careers page is the appropriate route to advertised roles and recruitment processes. An employee total in a standalone sustainability report should not be presented as the total workforce of every consolidated subsidiary. [16][3]
Sustainability & community programmes
The FY2025–26 business responsibility report explicitly states a standalone reporting boundary. It describes workforce, environmental and governance indicators for that scope rather than automatically covering every global group operation. The report states a target to reduce absolute Scope 1 and Scope 2 emissions by 35% by 2030 against a 2020 baseline. This is a target and should be kept separate from achieved annual performance. [3]
The CSR programme covers areas such as healthcare, education, water and sanitation, rural development and environmental initiatives. Analytical context: project spending, people reached and demonstrated long-term outcomes are different measures. Pharmaceutical manufacturing also has material questions around water, energy, effluent and waste. Sustainability reports and assurance statements provide the boundary and methodology needed to compare these measures over time. [17][18]
Key developments to the review date
The 2025 management transition and acquisition of Checkpoint form part of the recent company story, while the Organon agreement is a separate 2026 development. On 30 October 2026, Sun reported that integration planning for Organon was continuing and some regulatory approvals remained outstanding. The status is therefore presented as agreed and progressing rather than completed. [5][2][9][7]
Analytical context: later product approvals, licensing agreements or acquisitions may change the business mix without immediately changing every financial measure. A careful update should record the event date, territory, approval or completion status and relevant legal entity. The annual-report archive and quarterly disclosures offer a coherent trail for following those changes beyond the review date. [6]
Business risks & regulatory context
Analytical context: key pharmaceutical exposures include pricing pressure, generic competition, intellectual-property disputes, product-development uncertainty, regulatory approvals, manufacturing compliance, recalls and currency movements. Specialty growth and major acquisitions add launch, integration, financing and intangible-asset risks. An approved product can still face competition or commercial execution challenges; research expenditure does not guarantee an approval. [6][11]
A facility inspection observation, an agency classification, an import restriction and a final enforcement decision are different regulatory events. They should always be reported with the facility, date, regulator and current status. This profile does not infer current clearance or an unresolved violation from a general quality policy. It provides corporate context and original business explanation; medicine use should follow the applicable product information and a qualified healthcare professional. [12]
Frequently asked questions
Did Sun Pharma begin in 1983 or 1993?
The business began in 1983. The present listed legal entity was incorporated in 1993, as stated in its statutory sustainability disclosure. [2][3]
Where is it based?
Its corporate office is Sun House in Goregaon East, Mumbai. Its registered office is at Tandalja, Vadodara, Gujarat. [3]
Who is the Managing Director?
Kirti Ganorkar is Managing Director. Dilip Shanghvi is founder and Executive Chairman. [4][5]
What does the group sell?
Its portfolio includes formulations, innovative medicines, APIs and consumer-health products. These have different channels and regulatory requirements. [10]
Are innovative-medicine sales additional to regional sales?
They are a portfolio view across geographic markets. They should not be added again to the regional figures to create a larger total. [7]
Had Organon become a completed acquisition?
The 30 October 2026 update still described integration planning and remaining regulatory approvals. This profile retains the agreed, pending status. [9][7]
Is adjusted profit the same as reported profit?
No. The Q2 release provides both measures separately. Its adjusted figure is an issuer-defined presentation and does not replace the reported net profit. [7]
A plain-language business glossary
- Formulation
- A finished medicine in a defined dosage form and strength.
- API
- Active pharmaceutical ingredient, an input used in a finished medicine.
- Generic
- A medicine developed against an established reference product under applicable regulatory requirements.
- Innovative medicine
- A product category used by the company for its innovation-led portfolio.
- ANDA
- A US abbreviated new drug application, used for generic-product approval.
- Pharmacovigilance
- Monitoring and handling information about medicine safety after and during use.
- Consolidated accounts
- Financial reporting for the parent and included group entities.
- Standalone boundary
- Reporting for the listed legal company rather than the entire consolidated group.
Reports & research documents
Use financial statements for accounting figures, annual reports for the wider business and governance picture, and dated announcements for subsequent developments. Figures with different reporting boundaries or periods should be compared only after checking their definitions.
Sources, review date & editorial scope
Reviewed: 3 November 2026. This profile combines original explanations with the linked official company publications and regulatory filings. Financial tables retain their currency, period and reporting basis. Company targets, forecasts and product claims are attributed to their issuer.
Products, entities, locations and developments are selected for orientation. The linked disclosures contain fuller subsidiary registers, accounting notes, governance reports and risk information. A later filing may change a fact recorded here. Historical announcements are dated so they are not mistaken for current appointments or completed transactions.
- Company overview ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Milestones and recognitions ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- FY2025–26 business responsibility and sustainability report ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Board of directors ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Kirti Ganorkar appointment announcement, 13 June 2025 ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Annual reports and statutory report sections ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Q2 FY2026–27 financial release, 30 October 2026 ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Q2 FY2026–27 statutory consolidated results and exceptional-item notes ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Definitive agreement to acquire Organon, 27 April 2026 ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Product portfolio: formulations, OTC and APIs ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Research, innovation and technology ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Global quality systems ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Annual reports of subsidiary companies ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Quarterly shareholding patterns ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Corporate and investor contacts ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Careers and workplace information ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Corporate social responsibility ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
- Sustainability reports ↗Sun Pharmaceutical Industries Limited · reviewed 3 Nov 2026
Mumbai, Maharashtra · Healthcare